Atheroprotective effect of human apolipoprotein a5 in a mouse model of mixed dyslipidemia

Circulation Research

Volumn 103, Issue 5, 2008, Pages 450-453

  Mansouri, Roxane M ^a   Baugé, Eric ^a   Gervois, Philippe ^a   Fruchart Najib, Jamila ^a   Fiévet, Catherine ^a   Staels, Bart ^a,b   Fruchart, Jean Charles ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Atherosclerosis; Dyslipidemia; Fibrates; Human apolipoprotein A5; Mouse model

Indexed keywords

APOLIPOPROTEIN A5; FENOFIBRATE; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; APOA5 PROTEIN, HUMAN; APOLIPOPROTEIN A; APOLIPOPROTEIN E2; CHOLESTEROL;

ANIMAL EXPERIMENT; ARTICLE; ATHEROGENESIS; ATHEROPROTECTIVE EFFECT; BLOOD SAMPLING; C57BL 6 MOUSE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIET; DYSLIPIDEMIA; FOOD INTAKE; GENE EXPRESSION; HEART PROTECTION; HYPERTRIGLYCERIDEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSGENIC MOUSE; TRANSGENICS; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANIMAL FOOD; ATHEROSCLEROSIS; BLOOD; C57BL MOUSE; DISEASE MODEL; FAT INTAKE; FEMALE; GENETICS; HOMEOSTASIS; HUMAN; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMAL FEED; ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN E2; APOLIPOPROTEINS A; ATHEROSCLEROSIS; CHOLESTEROL; DIETARY FATS; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; FEMALE; HOMEOSTASIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROCETOFEN; TRIGLYCERIDES;

EID: 54049125406     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.179861     Document Type: Article

References (13)

1. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294:169-173.
2. Grosskopf I, Baroukh N, Lee SJ, Kamari Y, Harats D, Rubin EM, Pennacchio LA, Cooper AD. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyc-eride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol. 2005;25:2573-2579.
3. Priore Oliva C, Pisciotta L, Li Volti G, Sambataro MP, Cantafora A, Bellocchio A, Catapano A, Tarugi P, Bertolini S, Calandra S. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arte-rioscler Thromb Vasc Biol. 2005;25:411-417.
4. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, Havekes LM, Groen AK, van Dijk KW. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglycer-ide (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem. 2004;279:27941-27947.
5. Gerritsen G, van der Hoogt CC, Schaap FG, Voshol PJ, Kypreos KE, Maeda N, Groen AK, Havekes LM, Rensen PC, Willems van Dijk K. ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoAV, but unaffected by apoCIII-deficiency. J Lipid Res. 2008;49:1048-1055.
6. Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther. 2007;29:763-777.
7. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipo-proteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest. 1998; 102:130-135.
8. Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge E, Dehondt H, Staels B, Pennacchio LA, Rubin EM, Fruchart-Najib J, Fruchart JC. Apoli-poprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem. 2003;278:17982-17985.
9. Gervois P, Fruchart JC, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab. 2007;3:145-156.
10. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem. 2005;280:21553-21560.
11. Lai CQ, Arnett DK, Corella D, Straka RJ, Tsai MY, Peacock JM, Adiconis X, Parnell LD, Hixson JE, Province MA, Ordovas JM. Feno-fibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol. 2007; 27:1417-1425.
12. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571-580.
13. Rensen PC, van Dijk KW, Havekes LM. Apolipoprotein AV: low concentration, high impact. Arterioscler Thromb Vasc Biol. 2005;25:2445-2447.